medical guideline
首页
中医/中西医结合指南
肿瘤学指南
泌尿外科指南
关于我们
郑重声明
联系我们
首页
肿瘤学指南
检索结果
人体系统
运动
骨肿瘤
软组织肿瘤
骨与软组织肿瘤
硬纤维瘤
骶尾部畸胎瘤
神经
中枢神经系统肿瘤
嗜铬细胞瘤和副神经节瘤
副神经节瘤
胶质细胞瘤
前庭神经鞘瘤
星形胶质细胞瘤和少突胶质细胞瘤
弥漫性胶质瘤
神经纤维瘤
神经细胞瘤
神经内分泌肿瘤
内分泌
甲状腺肿瘤
垂体肿瘤
肾上腺肿瘤
甲状旁腺肿瘤
胸腺肿瘤
神经内分泌肿瘤
循环
心脏肿瘤
淋巴瘤
骨髓瘤
白血病
血液肿瘤
血管瘤
呼吸
肺癌
鼻咽癌
喉部肿瘤
下咽癌
鼻腔和副鼻窦癌
呼吸道肿瘤
鼻颅咽管瘤
淋巴管肌瘤
消化
胰腺肿瘤
口腔癌
肛门癌
口咽癌
胆囊癌
胆管肿瘤
直肠癌
结肠癌
胃癌
小肠癌
肝癌
大肠肿瘤
唾液腺癌
阑尾肿瘤
食管肿瘤
肝肿瘤
壶腹肿瘤
肝胆癌
结直肠肿瘤
食管胃肿瘤
胃肠道肿瘤
消化道肿瘤
泌尿
膀胱肿瘤
肾癌
脐尿管癌
尿路上皮癌
肾血管平滑肌脂肪瘤
泌尿生殖肿瘤
生殖
女性
子宫肿瘤
卵巢肿瘤
乳腺肿瘤
阴道肿瘤
输卵管癌
外阴癌
妊娠滋养细胞肿瘤
妇科肿瘤
男性
前列腺肿瘤
性索间质瘤
睾丸肿瘤
阴茎癌
男性乳腺肿瘤
泌尿生殖肿瘤
其他
症状管理
治疗方案
诊断/检测/评估方法
预防和筛查
COVID-19大流行癌症患者相关指导建议
皮肤肿瘤
黑色素瘤
头颈部肿瘤
康复营养
生育能力
体力活动
心理健康
腹膜肿瘤
实体瘤
胸部肿瘤
长期监测
Cowden综合征
转诊
遗传性癌症综合征
癌症患者其他类问题管理
寡转移性疾病
基因测序
易感基因变异的分类
外科肿瘤
罕见癌症
不明原因癌症
纤维瘤
腹部肿瘤
老年肿瘤
儿童/青少年肿瘤
人类微生物组与癌变
检索结果
按关键字
按标题
按关键词
按摘要
按作者
按期刊
按发表年份
共搜索到
61条
与
risk
有关的结果
Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update
2019年 发布于
American Society of Clinical Oncology
卷 第期
所属人体系统:
生殖
|
乳腺肿瘤
American Society of Clinical Oncology
Breast Cancer
Endocrine Therapy
Risk Reduction
指南简介
原文链接
Screening for Breast Cancer in Average-Risk Women: a Guidance Statement from the American College of Physicians
2019年 发布于
Ann Intern Med
170卷 第8期
所属人体系统:
生殖
|
乳腺肿瘤
American College of Physicians
Breast Cancer
Screening
Average-
risk
Women
Guideline
指南简介
原文链接
British Menopause Society Consensus Statement: the Risks and Benefits of HRT Before and after a Breast Cancer Diagnosis
2019年 发布于
Post Reproductive Health
25卷 第1期
所属人体系统:
生殖
|
乳腺肿瘤
British Menopause Society
Hormone Replacement Therapy
Lifestyle Risk Factors
Risk of Breast Cancer Diagnosis
Vasomotor Symptoms
指南简介
原文链接
USPSTF Guideline: Offer Risk-reducing Drugs to Women at Increased Risk for Breast Cancer and Low Risk for Adverse Effects
2019年 发布于
Ann Intern Med
171卷 第12期
所属人体系统:
生殖
|
乳腺肿瘤
US Preventive Services Task Force
Breast Cancer
Risk-reducing Drugs
Adverse Effects
指南简介
原文链接
S3 Guideline Breast Cancer: Update on Early Detection, and Mammography Screening
2019年 发布于
Radiologe
59卷 第1期
所属人体系统:
生殖
|
乳腺肿瘤
German Evidence- and Consensus-based (S3) Guideline
Aftercare
Breast Neoplasms
Early Detection of Cancer
Mammography
Risk Assessment
指南简介
原文链接
Diagnostic Value of Imaging (ultrasonography, Doppler, CT, MR, PET-CT) for the Diagnosis of a Suspicious Ovarian Mass and Staging of Ovarian, Tubal Or Primary Peritoneal Cancer: Article Drafted from the French Guidelines in Oncology Entitled `Initial Man
2019年 发布于
Gynecol Obstet Fertil Senol
47卷 第2期
所属人体系统:
其他
|
腹膜肿瘤
FRANCOGYN (Groupe Français De Recherche En Chirurgie Oncologique Et Gynécologique)
Au CNGOF (Collège National Des Gynécologues Obstétriciens Français)
À La SFOG (Société Française D’oncologie Gynécologique Et Au Groupe GINECO-ARCAGY (Groupe D’investigateurs Nationaux Pour L’étude Des Cancers Ovariens Et Du Sein – Association De Recherche Sur Les Cancers Dont Gynécologiques) Et Sont Labellisées Par L’INCa (Institut National Du Cancer).
Transvaginal Ultrasound Is the First-line Examination Allowing Characterizing 80 to 90% of Adnexal Masses (LP1). If Performed by an Expert
a Subjective Analysis Is Optimal. If Performed by a Non-expert
Combining the Use of Simple Rules with Subjective Analysis Can Achieve the Diagnostic Performance of an Expert (LP1). Whichever the Chosen Model (subjective Analysis by an Expert Or Combination of the Simple Rules with a Subjective Analysis by a Non-expert)
a Second-line Examination Will Have to Be Proposed in the Complex Or Indeterminate Cases (about 20% of the Masses) (grade A). the Best-performing Second-line Test for Characterization Is Pelvic MRI (LP1). If Read by an Expert
a Pathological Hypothesis Can Or Should Be Suggested (grade D). in Case of Non-expert Reading
the Use of the ADNEXMR Score Allows a Reliable Assessment of the Positive Predictive Value of Malignancy to Guide the Patient Towards the Best Management (gradeC). for Preoperative Assessment and Evaluation of Resectability of Ovarian
Fallopian Tube Or Primary Peritoneal Cancer
It Is Recommended to Perform a Chest Abdomen and Pelvis CT with Contrast Agent Injection (LP2
Grade B). in the Event of a Contraindication to the Injection of Iodinated Contrast Agent (severe Renal Insufficiency
GFR <30mL/min)
an Abdomen and Pelvis MRI Completed with a Non-injected Chest CT May Be Proposed (LP3
Grade C). by Analogy
the Same Examinations Are Recommended to Evaluate the Disease after Neo-adjuvant Chemotherapy (LP3
Recommendation Grade C). Further Studies Will Be Required to Determine Whether PET-CT Provides Better Lymph Node Assessment Before Retroperitoneal and Pelvic Lymphadenectomy. PET-CT May Be Used to Eliminate Lymph Node Involvement in the Absence of Suspicious Lymph Nodes on Morphological Examination (LP3
Grade C). the Report Should Specify the Localizations Leading to a Risk of Incomplete Cytoreductive Surgery and Lesions Outside the Field Explored During Surgery.
指南简介
原文链接
Management of Epithelial Cancer of the Ovary, Fallopian Tube, and Primary Peritoneum. Short Text of the French Clinical Practice Guidelines Issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and Endorsed by INCa
2019年 发布于
Eur J Obstet Gynecol Reprod Biol
236卷 第_期
所属人体系统:
其他
|
腹膜肿瘤
FRANçais De Recherche En Chirurgie Oncologique Et GYNécologique (FRANCOGYN)
Le Collège National Des Gynécologues Et Obstétriciens Français (CNGOF)
La Société Française D’oncologie Gynécologique (SFOG) Et Le Groupe D’investigateurs National Des Études Des Cancers Ovariens Et Du Sein (GINECO-ARCAGY) Et De L’institut National Du Cancer (INCa)
An MRI Is Recommended for an Ovarian Mass That Is Indeterminate on Ultrasound. the ROMA Score (combining CA125 and HE4) Can Also Be Calculated (Grade A). in Presumed Early-stage Ovarian Or Tubal Cancers
the Following Procedures Should Be Performed: an Omentectomy (at a Minimum
Infracolic)
an Appendectomy
Multiple Peritoneal Biopsies
Peritoneal Cytology (grade C)
and Pelvic and Para-aortic Lymphadenectomies (Grade B) for All Histologic Types
Except the Expansile Mucinous Subtypes
for Which Lymphadenectomies Can Be Omitted (grade C). Minimally Invasive Surgery Is Recommended for Early-stage Ovarian Cancer
When There Is No Risk of Tumor Rupture (grade B). Adjuvant Chemotherapy by Carboplatin and Paclitaxel Is Recommended for All High-grade Ovarian and Tubal Cancers (FIGO Stages I-IIA) (grade A). for FIGO Stage III Or IV Ovarian
Tubal
and Primary Peritoneal Cancers
a Contrast-enhanced Computed Tomography (CT) Scan of the Thorax/abdomen/pelvis Is Recommended (Grade B)
as Well as Laparoscopic Exploration to Take Multiple Biopsies (grade A) and a Carcinomatosis Score (Fagotti Score at a Minimum) (grade C) to Assess the Possibility of Complete Surgery (i.e.
Leaving No Macroscopic Tumor Residue). Complete Surgery by a Midline Laparotomy Is Recommended for Advanced Ovarian
Tubal
Or Primary Peritoneal Cancers (grade B). for Advanced Cancers
Para-aortic and Pelvic Lymphadenectomies Are Recommended When Metastatic Adenopathy Is Clinically Or Radiologically Suspected (grade B). When Adenopathy Is Not Suspected and When Complete Peritoneal Surgery Is Performed as the Initial Surgery for Advanced Cancer
the Lymphadenectomies Can Be Omitted Because They Do Not Modify Either the Medical Treatment Or Overall Survival (grade B). Primary Surgery (before Other Treatment) Is Recommended Whenever It Appears Possible to Leave No Tumor Residue (grade B). after Primary Surgery Is Complete
6 Cycles of Intravenous Chemotherapy (grade A) Are Recommended
Or a Discussion with the Patient About Intraperitoneal Chemotherapy
According to Her Risk-benefit Ratio. after Complete Interval Surgery for FIGO Stage III Disease
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Can Be Proposed
in Accordance with the Modalities of the OV-HIPEC Trial (grade B). in Cases of Postoperative Tumor Residue Or in FIGO Stage IV Tumors
Chemotherapy Associated with Bevacizumab Is Recommended (grade A).
指南简介
原文链接
Management of Epithelial Cancer of the Ovary, Fallopian Tube, and Primary Peritoneum. Long Text of the Joint French Clinical Practice Guidelines Issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and Endorsed by INCa. Part 1: Diagnostic Exploration and Staging, Surgery, Perioperative Care, and Pathology
2019年 发布于
Journal of Gynecology Obstetrics and Human Reproduction
48卷 第6期
所属人体系统:
其他
|
腹膜肿瘤
FRANçais De Recherche En Chirurgie Oncologique Et GYNécologique (FRANCOGYN)
Le Collège National Des Gynécologues Et Obstétriciens Français (CNGOF)
La Société Française D’oncologie Gynécologique (SFOG) Et Le Groupe D’investigateurs National Des Études Des Cancers Ovariens Et Du Sein (GINECO-ARCAGY) Et De L’institut National Du Cancer (INCa)
An MRI Is Recommended for an Ovarian Mass That Is Indeterminate on Ultrasound. the ROMA Score (combining CA125 and HE4) Can Also Be Calculated (grade A). in Presumed Early-stage Ovarian Or Tubal Cancers
the Following Procedures Should Be Performed: an Omentectomy (at a Minimum
Infracolic)
an Appendectomy
Multiple Peritoneal Biopsies
Peritoneal Cytology (grade C)
and Pelvic and Para-aortic Lymphadenectomies (grade B) for All Histologic Types
Except the Expansile Mucinous Subtypes
for Which Lymphadenectomies Can Be Omitted (grade C). Minimally Invasive Surgery Is Recommended for Early-stage Ovarian Cancer
When There Is No Risk of Tumor Rupture (grade B). for FIGO Stages III Or IV Ovarian
Tubal
and Primary Peritoneal Cancers
a Contrast-enhanced Computed Tomography (CT) Scan of the Thorax/abdomen/pelvis Is Recommended (grade B)
as Well as Laparoscopic Exploration to Take Multiple Biopsies (grade A) and a Carcinomatosis Score (Fagotti Score at a Minimum) (grade C) to Assess the Possibility of Complete Surgery (i.e.
Leaving No Macroscopic Tumor Residue). Complete Surgery by a Midline Laparotomy Is Recommended for Advanced Ovarian
Tubal
Or Primary Peritoneal Cancer (grade B). for Advanced Cancers
Para-aortic and Pelvic Lymphadenectomies Are Recommended When Metastatic Adenopathy Is Clinically Or Radiologically Suspected (grade B). When Adenopathy Is Not Suspected and When Complete Peritoneal Surgery Is Performed as the Initial Surgery for Advanced Cancer
the Lymphadenectomies Can Be Omitted Because They Do Not Modify Either the Medical Treatment Or Overall Survival (grade B). Primary Surgery (before Other Treatment) Is Recommended Whenever It Appears Possible to Leave No Tumor Residue (grade B).
指南简介
原文链接
Radiation Dose Constraints for Organs at Risk in Neuro-oncology; the European Particle Therapy Network Consensus
2018年 发布于
Radiother Oncol
128卷 第1期
所属人体系统:
神经
|
神经细胞瘤
The European Particle Therapy Network
Dose Constraints
European Particle Therapy Network
Organs at Risk
Particle Therapy
指南简介
原文链接
Bladder Cancer: Overview and Disease Management. Part 1: Non-muscle-invasive Bladder Cancer
2018年 发布于
Br J Nurs
27卷 第9期
所属人体系统:
泌尿
|
膀胱肿瘤
无
Bladder Cancer
Management
Non-muscle-invasive Bladder Cancer
Oncology
Risk Factors
指南简介
原文链接
Initial Diagnostic Work-Up of Acute Leukemia
2018年 发布于
American Society of Clinical Oncology
卷 第期
所属人体系统:
循环
|
白血病
American Society of Clinical Oncology
Acute Leukemia
Initial Diagnostic
central Nervous System (CNS)
molecular Diagnosis
Potential Markers
risk
Stratification
target Therapy
指南简介
原文链接
Contraception and Cancer: CNGOF Contraception Guidelines
2018年 发布于
Gynécologie Obstétrique Fertilité & Sénologie
46卷 第12期
所属人体系统:
其他
|
癌症患者其他类问题管理
无
ContraceptionCancer RiskContraception after CancerBreast CancerCancer RecurrenceClinical Guidelines
指南简介
原文链接
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update
2018年 发布于
Eur Urol
73卷 第1期
所属人体系统:
泌尿
|
尿路上皮癌
European Association of Urology
Cytology
Guidelines
Nephroureterectomy
Renal Pelvis
Risk Factors
Survival
Ureter
Ureteroscopy
Urinary Tract Cancer
Urothelial Carcinoma
指南简介
原文链接
Incorporating Coexisting Chronic Illness Into Decisions About Patient Selection for Lung Cancer Screening. an Official American Thoracic Society Research Statement
2018年 发布于
Am J Respir Crit Care Med
198卷 第2期
所属人体系统:
呼吸
|
肺癌
American Thoracic Society
Communication of Risk
Comorbidities
Lung Cancer Screening
指南简介
原文链接
Society for Translational Medicine Expert Consensus on the Preoperative Assessment of Circulatory and Cardiac Functions and Criteria for the Assessment of Risk Factors in Patients with Lung Cancer
2018年 发布于
J Thorac Dis
10卷 第9期
所属人体系统:
呼吸
|
肺癌
无
Lung Cancer
Cardiovascular Functions
criteria
Assessment of Risk Factors
指南简介
原文链接
Management of Actinic Keratosis at Specific Body Sites in Patients at High Risk of Carcinoma Lesions: Expert Consensus from the AKTeam™ of Expert Clinicians
2018年 发布于
J Eur Acad Dermatol Venereol
32卷 第3期
所属人体系统:
其他
|
症状管理
无
Management
actinic Keratosis
High Risk of Carcinoma Lesions
指南简介
原文链接
Pembrolizumab for Adjuvant Treatment of Resected Melanoma with High Risk of Recurrence
2018年 发布于
National Institute for Health and Care Excellence
卷 第期
所属人体系统:
其他
|
黑色素瘤
National Institute for Health and Care Excellence
Melanoma
Pembrolizumab
high Risk
recurrence
指南简介
原文链接
S3 Guideline Breast Cancer: Update on Early Detection, and Mammography Screening
2018年 发布于
Radiologe
59卷 第1期
所属人体系统:
生殖
|
乳腺肿瘤
无
Aftercare
Breast Neoplasms
Early Detection of Cancer
Mammography
Risk Assessment
指南简介
原文链接
Consensus Statement on Definition, Diagnosis, and Management of High-risk Prostate Cancer Patients on Behalf of the Spanish Groups of Uro-Oncology Societies URONCOR, GUO, and SOGUG
2018年 发布于
Clin Transl Oncol
20卷 第3期
所属人体系统:
生殖
|
前列腺肿瘤
Spanish Society of Urological Oncology
Chemotherapy
High-
risk
Prostate Cancer
Prostate Cancer
Radiotherapy
Surgery
指南简介
原文链接
Management of Patients with Advanced Prostate Cancer: the Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 [Figure Presented]
2018年 发布于
Eur Urol
73卷 第2期
所属人体系统:
生殖
|
前列腺肿瘤
The Advanced Prostate Cancer Consensus Conference (APCCC) 2017
Advanced and High-
risk
Localized Prostate Cancer
Castration-naive and Castration-resistant Prostate Cancer
Consensus
Oligometastatic Prostate Cancer
Therapeutics
指南简介
原文链接
首页
上一页
1
2
3
4
下一页
尾页
共61条,每页显示
20条
50条
100条
跳转至第
页
确定